The use of molecular options for detection of is increasing in clinical laboratories. molecular strategies were a lot more likely to identify in specimens than those using an EIA. Two strains had been distributed using the sections: an PD173074 L2 laboratory-adapted stress and an uncharacterized major isolate. Further evaluation indicated a notable difference in recognition of between particular strategies only using the L2 stress at lower concentrations. Furthermore eight adverse specimens had been distributed and fake positives were discovered to be uncommon by all strategies contained in the research. can be an important sexually sent pathogen that triggers top and lower genital system infections in men and women resulting in endometritis infertility and attacks from PD173074 the neonate. Clinical specimens that are examined for consist of endocervical swabs urethral swabs urine specimens conjunctival swabs and vulvovaginal swabs. Traditional tests relied on cell tradition and/or recognition of by enzyme immunosorbent assays (EIA) or immunofluorescence (IF). Because of the low level of sensitivity of culture the brand new “yellow metal standard ” referred to as the extended yellow metal standard requires a positive result become confirmed by do it again testing having a different assay (25 28 Many molecular testing or nucleic acidity amplification testing (NAAT) including BDProbeTecET Gen-Probe AMP-CT Gen-Probe APTIMA Combo 2 Roche AMPLICOR CT/NG and Roche COBAS AMPLICOR CT/NG are actually commercially obtainable; some are no more obtainable (Abbott LCx); and fresh technologies such as for example molecular beacons are becoming developed (1). Earlier studies possess attributed discrepant outcomes with NAAT to inhibitors in the specimens inappropriate specimen handling cross-contamination or poor sensitivity (4 7 10 11 16 19 23 24 The reporting of false-positive results has medical social and psychological effects on the patient and results in increased health IFNA2 care costs and inappropriate treatment (6). The United Kingdom PD173074 National External Quality Assessment Scheme for Microbiology (UK NEQAS for Microbiology) has specialized in the production and performance analysis of external quality assessment (EQA) panels for a wide range of bacteria fungi parasites and viruses for more than 30 years. An EQA panel for the detection of by EIA and IF was introduced in 1991 and more-challenging specimens specifically designed to test NAAT methods have been included in the scheme from 2002. In addition to the EIA-IF schemes a pilot scheme for the molecular detection of is under development and panels for testing by NAAT methods only have been distributed recently. Verkooyen et al. (26) described the results obtained from an international EQA scheme consisting of freeze-dried urine specimens. The authors reported difficulty in the detection of at lower concentrations and found no difference between the NAAT methods Roche AMPLICOR CT/NG Roche COBAS AMPLICOR CT/NG and Abbott LCx. Accurate detection of was common ranging from 89 to 100%. A further EQA study of detection of in urine samples based in Australia found varying performance depending on the concentration (0 to 100%) and reported that low-level positives could not be detected consistently by a single test (18). In contrast to the results reported by Verkooyen et al. (26) Land et al. (18) found that at lower concentrations of in female specimens (urine and swabs) and found no difference among three commercial tests (Abbott LCx Gen-Probe AMP-CT and Roche COBAS AMPLICOR CT/NG). The aim of this retrospective study was to analyze the effective detection of in simulated endocervical swab specimens by clinical laboratories participating in the EIA and molecular EQA schemes distributed internationally by UK NEQAS for Microbiology between January 2002 and June 2004. Negative specimens PD173074 and those that were designed to challenge participants by PD173074 including low levels of elementary bodies (EB) per milliliter were included in the PD173074 study. Two strains were included in the study: one L2 laboratory-adapted strain and one primary clinical isolate. Due to the large number of participants in the study additional data were collected that provided insight into the differential performance of the methodologies in use in clinical laboratories. Therefore the accurate detection of by participants different methods (EIA or NAAT) and commercial assays was compared with the EQA specimens.